Screener
Inhibrx Biosciences, Inc. INBX Business Segments — G&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0002007919-26-000027
| Line item | THREE MONTHS ENDEDMARCH 31, 2026 | THREE MONTHS ENDEDMARCH 31, 2025 |
|---|---|---|
| Other research and development | (2,906) | (3,153) |
| Total research and development expense | (25,217) | (36,877) |
| General and administrative expense | ||
| Personnel | (3,646) | (3,777) |
| Other general and administrative | (2,064) | (2,247) |
| Total general and administrative expense | (5,710) | (6,024) |
| Other expense | (2,514) | (410) |
| Segment and consolidated net loss | $(33,441) | $(43,311) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Inhibrx Biosciences, Inc.'s business segments — G&A?
- Inhibrx Biosciences, Inc. (INBX) reported business segments — G&A of $5.71M in Q1 2026.
- What does business segments — G&A mean?
- This metric aggregates all general and administrative expenses, including personnel, legal, and corporate overhead. It represents the total cost of running the business operations and supporting the company's infrastructure. It is a key indicator of the company's operational burn rate and corporate cost structure.
Ask your AI about Inhibrx Biosciences, Inc.'s business segments — g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude